Next-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations Meeting Abstract
| Authors: | Turner, N. C.; Laird, A. D.; Telli, M. L.; Rugo, H. S.; Mailliez, A.; Ettl, J.; Grischke, E. M.; Mina, L. A.; Balmaña, J.; Fasching, P. A.; Hurvitz, S. A.; Albacker, L. A.; Frampton, G. M.; Chelliserry, J.; Bycott, P.; Conte, U.; Wardley, A. M.; Robson, M. E. |
| Abstract Title: | Next-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations |
| Meeting Title: | 44th ESMO Congress (ESMO 2019) |
| Journal Title: | Annals of Oncology |
| Volume: | 30 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2019 Sep 27-Oct 1 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2019-10-01 |
| Start Page: | mdz242.009 |
| Language: | English |
| ACCESSION: | WOS:000491295501131 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdz242.009 |
| Notes: | Meeting Abstract: 314P -- Appears on pages v108-v109 of the abstract book -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work